Compare Apple Inc (AAPL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs TG Therapeutics Inc — how do they compare? Apple Inc trades at $302.1 (market cap $4.45T), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Apple Inc is far larger — about 582.5× TG Therapeutics Inc's market cap, and Apple Inc pays a 0.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AAPL | TGTX | |
|---|---|---|
Market Cap | $4.45T | $7.64B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $59.06 |
52-Week Low | $224.90 | $26.94 |
Enterprise Value | $4.47T | $7.84B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.42, down 2.22% on the day, with a bearish technical signal. The stock shows strong fundamentals, including a 26.91% net income margin and consistent earnings beats. Recent news highlights Apple's leadership in smartphone shipments and AI potential through its 2.5 billion active devices, though it faces challenges from union disputes and potential earnings pressure.
Outlook remains positive with a consensus price target of $337.63, implying 12% upside. Risks include weaker iPhone sales, regulatory scrutiny from EU fines, and competitive pressures. Analyst sentiment is bullish (63.64% buy ratings), but technical weakness and near-term headwinds warrant caution.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
